NDLI: Salvage Therapy of Multiple Myeloma: The New Generation Drugs

Content Provider	PubMed Central
Author	Romano, Alessandra Conticello, Concetta Cavalli, Maide Calogero, Vetro Raimondo, Cosimo Di Martina, Valentina Di Elena, Schinocca Fauci, Alessia La Parrinello, Nunziatina Laura Chiarenza, Annalisa Raimondo, Francesco Di
Copyright Year	2014
Abstract	During the past decade, overall results of treatment of multiple myeloma (MM) have been improved and survival curves are now significantly better with respect to those obtained with historical treatment. These improvements are linked to a deeper knowledge of the biology of disease and to the introduction in clinical practice of drugs with different mechanism of action such as proteasome inhibitors and immunomodulatory drugs (IMiDs). However, MM remains in most cases an incurable disease. For patients who relapse after treatment with novel agents, the prognosis is dismal and new drugs and therapeutic strategies are required for continued disease control. In this review, we summarize new insights in salvage therapy for relapsed/refractory MM as emerging from recent clinical trials exploring the activity of bendamustine, new generation proteasome inhibitors, novel IMiDs, monoclonal antibodies, and drugs interfering with growth pathways.
Related Links	http://dx.doi.org/10.1155/2014/456037
Starting Page	456037
File Format	PDF
ISSN	23146133
e-ISSN	23146141
Journal	BioMed Research International
Volume Number	2014
Language	English
Publisher	Hindawi Publishing Corporation
Publisher Date	2014-01-01
Access Restriction	Open
Rights Holder	Hindawi Publishing Corporation
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Microbiology Medicine Biochemistry, Genetics and Molecular Biology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells

Smoldering Multiple Myeloma

New Insights in the Mobilization of Hematopoietic Stem Cells in Lymphoma and Multiple Myeloma Patients

Serum Parathyroid Hormone Is a New Potential Risk Factor in Multiple Myeloma

Implications of Heterogeneity in Multiple Myeloma

New therapies in multiple myeloma

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma

Immunological Dysregulation in Multiple Myeloma Microenvironment

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2

Salvage Therapy of Multiple Myeloma: The New Generation Drugs

Similar Documents

Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells

Smoldering Multiple Myeloma

New Insights in the Mobilization of Hematopoietic Stem Cells in Lymphoma and Multiple Myeloma Patients

Serum Parathyroid Hormone Is a New Potential Risk Factor in Multiple Myeloma

Implications of Heterogeneity in Multiple Myeloma

New therapies in multiple myeloma

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma

Immunological Dysregulation in Multiple Myeloma Microenvironment

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2

Salvage Therapy of Multiple Myeloma: The New Generation Drugs